We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Chengdu Kanghong Pharmaceutical Group, has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept.